2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
- PMID: 16239238
- DOI: 10.1093/annonc/mdi961
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Similar articles
-
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Ann Oncol. 2017. PMID: 29232472 Free PMC article. Review.
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
-
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282. Int J Gynecol Cancer. 2014. PMID: 25341581 Review.
-
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568. Int J Gynecol Cancer. 2011. PMID: 21543936 Review.
-
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446. Int J Gynecol Cancer. 2011. PMID: 21543935
Cited by
-
Chemotherapy for Elderly Ovarian Cancer Patients.Gynecol Obstet (Sunnyvale). 2016 Aug;6(8):397. doi: 10.4172/2161-0932.1000397. Epub 2016 Aug 31. Gynecol Obstet (Sunnyvale). 2016. PMID: 27695647 Free PMC article.
-
Treatment guidelines in ovarian cancer.Clin Transl Oncol. 2007 May;9(5):308-16. doi: 10.1007/s12094-007-0058-8. Clin Transl Oncol. 2007. PMID: 17525041
-
Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.Oncol Lett. 2018 Oct;16(4):4586-4592. doi: 10.3892/ol.2018.9232. Epub 2018 Jul 30. Oncol Lett. 2018. PMID: 30214593 Free PMC article.
-
Chemotherapy: Current drugs still have potential in advanced ovarian cancer.Nat Rev Clin Oncol. 2010 Apr;7(4):191-3. doi: 10.1038/nrclinonc.2010.37. Nat Rev Clin Oncol. 2010. PMID: 20354543 Clinical Trial.
-
In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery.J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):31-36. doi: 10.4274/jtgga.galenos.2018.2018.0015. Epub 2018 Mar 16. J Turk Ger Gynecol Assoc. 2019. PMID: 29545229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical